Drugs / IL-5 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07257640 | Nov 2025 → Nov 2028 expected | hematologic disorder, neoplasm | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-5 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07257640 ↗ |
| Modality | Cell therapy | “IL-5 CAR-T cell therapy” NCT07257640 ↗ |
| Route | Intravenous | “Each subject receive IL-5 CAR T-cells by intravenous infusion” NCT07257640 ↗ |